PRECIGEN INC (PGEN)
Sector: Health Care
2026 Annual Meeting Analysis
PRECIGEN INC · Meeting: June 18, 2026
Directors FOR
9
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
PGEN's 3-year price return of +268.1% vastly outperforms the XBI (SPDR S&P Biotech ETF) benchmark by +207.2 percentage points, well above the 65-point threshold needed to trigger a concern; no overboarding, attendance, or independence flags apply to Mr. Kirk, who joined in 2008.
Ms. Howell Agee joined in July 2024, which is within the 24-month new-director exemption period, so the TSR trigger does not apply; she holds two outside public board seats, which is within the permitted limit for a non-executive director.
PGEN's strong outperformance versus XBI (SPDR S&P Biotech ETF) means the TSR trigger does not apply; Mr. Alvarez has no overboarding or attendance concerns noted.
PGEN's strong outperformance versus XBI (SPDR S&P Biotech ETF) means the TSR trigger does not apply; Mr. Frank holds one outside public board seat and has extensive healthcare investment banking experience relevant to PGEN's business.
The proxy discloses that Vinita Gupta was the only director who did not attend at least 75% of combined board and committee meetings in 2025, which triggers a No vote under our policy; however, all other indicators are positive, including PGEN's strong stock outperformance versus XBI (SPDR S&P Biotech ETF) and her relevant pharmaceutical industry expertise — nonetheless, the attendance policy threshold is clear and a FOR vote cannot be supported given this disclosure.
PGEN's strong outperformance versus XBI (SPDR S&P Biotech ETF) means the TSR trigger does not apply; Mr. Hassan has deep pharmaceutical industry leadership experience and no overboarding concerns.
PGEN's strong outperformance versus XBI (SPDR S&P Biotech ETF) means the TSR trigger does not apply; Mr. Kindler qualifies as an audit committee financial expert and has relevant biopharmaceutical CEO and legal experience.
As CEO-director, Dr. Sabzevari is subject to the same TSR trigger as all other directors; PGEN's +268.1% three-year return outperforms XBI (SPDR S&P Biotech ETF) by +207.2 percentage points, far exceeding the 65-point threshold, so the trigger does not fire.
PGEN's strong outperformance versus XBI (SPDR S&P Biotech ETF) means the TSR trigger does not apply; Mr. Turley has extensive accounting and financial expertise as former Ernst & Young Chairman and CEO with no overboarding concerns.
Eight of nine director nominees receive a FOR vote; Vinita Gupta receives an AGAINST vote solely because the proxy discloses she was the only director who attended fewer than 75% of combined board and committee meetings in 2025, triggering the attendance policy threshold. PGEN's exceptional stock performance — a three-year return of +268.1% versus the XBI (SPDR S&P Biotech ETF) benchmark return of +60.9%, a gap of +207.2 percentage points — means the TSR underperformance trigger does not fire for any director. The director slate is otherwise well-qualified with relevant pharmaceutical and biotechnology experience.
Say on Pay
✓ FORCEO
Helen Sabzevari
Total Comp
$5,354,329
Prior Support
97.9%%
CEO total compensation of approximately $5.35 million is reasonable for a biotech company of PGEN's size and stage, particularly given the FDA approval of Papzimeos in 2025 — a landmark commercial milestone. The pay structure is appropriately weighted toward variable compensation, with 77% of the CEO's target pay classified as at-risk, and annual bonuses were tied to specific, measurable operational goals including FDA approval, European regulatory filing, and commercial launch metrics. Last year's say-on-pay vote received 97.9% support, and the company has a meaningful clawback policy in place; no policy triggers fire here.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
7 yrs
Audit Fees
$1,302,100
Non-Audit Fees
$1,900
Deloitte has served as PGEN's auditor since 2019, giving it approximately seven years of tenure — well below the 25-year threshold that would trigger a concern. Non-audit fees of $1,900 represent less than 0.2% of audit fees of $1,302,100, far below the 50% threshold. Deloitte is a Big 4 firm appropriate for a company of PGEN's $1.5 billion market cap, and no material restatements have been disclosed.
Overall Assessment
The 2026 PGEN annual meeting ballot is straightforward: eight of nine director nominees are recommended FOR, with Vinita Gupta receiving an AGAINST vote due to below-75% meeting attendance disclosed in the proxy; the auditor ratification and say-on-pay proposals both pass all policy screens cleanly, supported by minimal non-audit fees, a seven-year auditor tenure, exceptional stock performance relative to XBI (SPDR S&P Biotech ETF), and a well-structured pay program tied to the company's landmark FDA approval of Papzimeos. The equity plan share increase (Proposal 4) falls outside the scope of this policy and no determination is made.
Compensation Peer Group
5 companies disclosed in 2026 proxy filing